[{"id":"8f439945-e5eb-40b9-a7e6-6eb64cdd7790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409161","created_at":"2021-01-18T05:47:46.957Z","updated_at":"2025-02-25T17:35:27.084Z","phase":"Phase 2","brief_title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT01409161","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 12/18/2025","study_completion_date":" 12/18/2025","last_update_posted":"2025-01-28"},{"id":"eae87f81-b151-4534-856f-6fe520d9c93c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04793919","created_at":"2024-04-15T17:24:45.119Z","updated_at":"2024-07-02T16:35:09.764Z","phase":"Phase 2","brief_title":"Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT04793919","lead_sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 10/09/2025","primary_completion_date":" 10/09/2025","study_txt":" Completion: 10/10/2027","study_completion_date":" 10/10/2027","last_update_posted":"2024-04-15"},{"id":"2aab645e-82e6-4871-a584-636d0a665d5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897490","created_at":"2021-05-21T11:52:52.627Z","updated_at":"2024-07-02T16:35:24.138Z","phase":"","brief_title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","source_id_and_acronym":"NCT04897490","lead_sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","biomarkers":" BCR","pipe":" | ","alterations":" FLT3 mutation","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-09"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"d3fbe9fc-cb0c-4ea4-a0c8-0aaa88366b82","acronym":"TUD-APOLLO-064","url":"https://clinicaltrials.gov/study/NCT02688140","created_at":"2022-03-24T01:54:02.216Z","updated_at":"2024-07-02T16:35:30.678Z","phase":"Phase 3","brief_title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02688140 - TUD-APOLLO-064","lead_sponsor":"Technische Universität Dresden","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-02"},{"id":"097d720f-4010-4e1e-98d1-33f41b29d5be","acronym":"","url":"https://clinicaltrials.gov/study/NCT05721872","created_at":"2023-02-10T16:00:37.438Z","updated_at":"2024-07-02T16:35:55.845Z","phase":"Phase 1/2","brief_title":"Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05721872","lead_sponsor":"Nazarbayev University","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-02-10"},{"id":"e1dbc9ad-9412-4aaf-92bd-41604f1ff173","acronym":"PANDA-T0","url":"https://clinicaltrials.gov/study/NCT03855371","created_at":"2021-01-18T19:01:37.325Z","updated_at":"2024-07-02T16:36:01.036Z","phase":"Phase 1","brief_title":"Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS","source_id_and_acronym":"NCT03855371 - PANDA-T0","lead_sponsor":"Ruijin Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 01/10/2018","start_date":" 01/10/2018","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-11-04"},{"id":"a38ba7d6-a220-4bff-9bf0-90309625cd62","acronym":"APL0406","url":"https://clinicaltrials.gov/study/NCT00482833","created_at":"2021-03-29T12:16:38.586Z","updated_at":"2024-07-02T16:36:02.654Z","phase":"Phase 3","brief_title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","source_id_and_acronym":"NCT00482833 - APL0406","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idarubicin hydrochloride • arsenic trioxide • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 276","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 10/17/2019","study_completion_date":" 10/17/2019","last_update_posted":"2022-10-11"},{"id":"edf89ed2-9472-419c-85d1-6866f6a5eba7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04689815","created_at":"2021-01-19T20:48:24.383Z","updated_at":"2025-02-25T13:49:02.921Z","phase":"Phase 2","brief_title":"Oral Arsenic Trioxide for NPM1-mutated AML","source_id_and_acronym":"NCT04689815","lead_sponsor":"The University of Hong Kong","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-10-04"},{"id":"74b84726-5dfa-4905-ad2e-aecfba9ada28","acronym":"","url":"https://clinicaltrials.gov/study/NCT02200978","created_at":"2021-01-18T10:17:32.797Z","updated_at":"2024-07-02T16:36:10.731Z","phase":"Phase 4","brief_title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","source_id_and_acronym":"NCT02200978","lead_sponsor":"South China Children's Leukemia Group","biomarkers":" PML","pipe":" | ","alterations":" RARA positive","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RARA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-05-10"},{"id":"1cd520b7-d95a-4e1c-8a44-c5ccf4757525","acronym":"","url":"https://clinicaltrials.gov/study/NCT04518501","created_at":"2021-01-18T21:38:58.859Z","updated_at":"2024-07-02T16:36:18.039Z","phase":"Phase 1/2","brief_title":"Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer","source_id_and_acronym":"NCT04518501","lead_sponsor":"Xing Xie","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • MUC16 elevation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • AiRuiYi (fluzoparib) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2022-01-25"},{"id":"8a7bbd71-8642-4694-a50d-cc6f1326a302","acronym":"","url":"https://clinicaltrials.gov/study/NCT01404949","created_at":"2021-01-18T05:46:30.343Z","updated_at":"2024-07-02T16:36:20.058Z","phase":"Phase 2","brief_title":"Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy","source_id_and_acronym":"NCT01404949","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TERT • PML","pipe":"","alterations":" ","tags":["TERT • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-11-30"},{"id":"cd2a2120-8206-4bc7-97e5-99651be9b52b","acronym":"Ara-C","url":"https://clinicaltrials.gov/study/NCT01191541","created_at":"2021-02-21T23:52:19.111Z","updated_at":"2024-07-02T16:36:26.660Z","phase":"Phase 4","brief_title":"Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)","source_id_and_acronym":"NCT01191541 - Ara-C","lead_sponsor":"Xiaofan Zhu","biomarkers":" RARA","pipe":"","alterations":" ","tags":["RARA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2021-08-10"},{"id":"218b3f32-98aa-43d5-b906-cca1ea6a94d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04869475","created_at":"2021-05-03T12:04:32.276Z","updated_at":"2024-07-02T16:36:30.320Z","phase":"Phase 2","brief_title":"Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation","source_id_and_acronym":"NCT04869475","lead_sponsor":"Ruijin Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2021-05-13"},{"id":"b54241ce-5516-4e32-9e9c-9ebd52694fc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04695223","created_at":"2021-01-19T20:49:25.952Z","updated_at":"2024-07-02T16:36:36.546Z","phase":"Phase 2","brief_title":"Arsenic Trioxide for Structural p53 Mutations","source_id_and_acronym":"NCT04695223","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 10/31/2021","study_completion_date":" 10/31/2021","last_update_posted":"2021-01-06"},{"id":"3bc31b45-5f1f-40d3-b8cd-4e6fcb568ed2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04489706","created_at":"2021-01-18T21:34:22.757Z","updated_at":"2024-07-02T16:36:42.695Z","phase":"","brief_title":"Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation","source_id_and_acronym":"NCT04489706","lead_sponsor":"Ruijin Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/28/2020","start_date":" 06/28/2020","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2020-07-28"},{"id":"e5587414-ede2-4832-a20e-9bd4ff957340","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031249","created_at":"2021-01-18T14:55:11.899Z","updated_at":"2024-07-02T16:36:47.929Z","phase":"Phase 1/2","brief_title":"Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03031249","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 02/08/2017","start_date":" 02/08/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-03-20"},{"id":"ca1cce76-4da6-4fbf-bdfa-002e28a88250","acronym":"APL2012","url":"https://clinicaltrials.gov/study/NCT01987297","created_at":"2022-05-31T05:55:44.114Z","updated_at":"2024-07-02T16:36:56.825Z","phase":"Phase 4","brief_title":"Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL","source_id_and_acronym":"NCT01987297 - APL2012","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • idarubicin hydrochloride • arsenic trioxide"],"overall_status":"Unknown status","enrollment":" Enrollment 738","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2019-08-19"},{"id":"52fed3d4-413e-4097-86f8-0092fe2f7147","acronym":"","url":"https://clinicaltrials.gov/study/NCT00413166","created_at":"2021-01-18T01:27:04.006Z","updated_at":"2024-07-02T16:36:59.866Z","phase":"Phase 2","brief_title":"All-trans Retinoic Acid, and Arsenic +/- Idarubicin","source_id_and_acronym":"NCT00413166","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2019-05-07"},{"id":"178c0736-cfc2-4e01-952f-bd1c2245a857","acronym":"","url":"https://clinicaltrials.gov/study/NCT03048344","created_at":"2021-01-18T15:00:43.403Z","updated_at":"2024-07-02T16:37:01.361Z","phase":"Phase 1","brief_title":"A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders","source_id_and_acronym":"NCT03048344","lead_sponsor":"Orsenix LLC","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide • arsenic trioxide oral (SY-2101)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/02/2016","start_date":" 12/02/2016","primary_txt":" Primary completion: 02/28/2019","primary_completion_date":" 02/28/2019","study_txt":" Completion: 02/28/2019","study_completion_date":" 02/28/2019","last_update_posted":"2019-03-25"},{"id":"09f2a25e-f9c4-4e8f-b462-a9ff0a46c7f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006091","created_at":"2021-01-17T23:52:36.950Z","updated_at":"2025-02-25T16:21:16.616Z","phase":"Phase 2","brief_title":"Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment","source_id_and_acronym":"NCT00006091","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCR","pipe":"","alterations":" ","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/19/2000","start_date":" 06/19/2000","primary_txt":" Primary completion: 01/01/2002","primary_completion_date":" 01/01/2002","study_txt":" Completion: 01/01/2002","study_completion_date":" 01/01/2002","last_update_posted":"2018-11-14"},{"id":"2906614a-082a-4755-8e4a-1ded335c88ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT01791894","created_at":"2021-01-18T07:56:09.898Z","updated_at":"2024-07-02T16:37:10.200Z","phase":"Phase 1/2","brief_title":"Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma","source_id_and_acronym":"NCT01791894","lead_sponsor":"Stanford University","biomarkers":" GLI2","pipe":"","alterations":" ","tags":["GLI2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2018-06-08"},{"id":"4198ff9d-9a8b-407f-b426-bbc6dd3a0d9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01835288","created_at":"2021-01-18T08:10:16.908Z","updated_at":"2024-07-02T16:37:10.623Z","phase":"Phase 2","brief_title":"Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT01835288","lead_sponsor":"Stanford University","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arsenic trioxide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2018-05-21"},{"id":"eafbc388-f756-4bca-a392-b9c43697f6d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03381781","created_at":"2021-01-18T16:41:14.908Z","updated_at":"2024-07-02T16:37:15.106Z","phase":"Phase 2","brief_title":"Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations","source_id_and_acronym":"NCT03381781","lead_sponsor":"Li Junmin","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • arsenic trioxide"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2018-01-04"}]